Eli Lilly | LLY - تكلفة المبيعات





تكلفة المبيعات تغيير تاريخ
AbbVie USD 4.22B 329M 2026-03
Abbott USD 5.3B 380M 2026-03
ALKERMES USD 73.25M 27.04M 2026-03
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Baxter International USD 1.81B 587M 2026-03
Biogen USD 797.5M 302M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Drreddys Laboratories INR 40.46B 3.64B 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Gilead Sciences USD 1.44B 174M 2026-03
GlaxoSmithKline GBP 1.88B 736M 2026-03
Glaxosmithkline GBP 3.47B 461.37M 2025-12
J&J USD 8.07B 103M 2026-03
Medtronic USD 3.8B 195M 2026-03
Merck USD 2.94B 380M 2026-03
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novartis USD 3.46B 83M 2026-03
Novartis USD 3.54B 7M 2025-12
Novo Nordisk DKK 13.6B 1.55B 2026-03
Perrigo USD 643.7M 103.7M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Phibro Animal Health USD 240.42M 2.58M 2025-12
Prestige Brands USD 140.76M 9.53M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sanofi EUR 3.67B 621M 2026-03
Sanofi EUR 3.76B 344M 2025-12
United Therapeutics USD 133.4M 341.3M 2026-03
Zoetis USD 672M 71M 2026-03